Industry Urges FDA to Reduce Scrutiny of Low-Risk Importers
This article was originally published in The Gold Sheet
The pharmaceutical industry generally supports the idea of FDA proposing a certified importer program for highly compliant manufacturers but urges caution in how risk levels for different importers would be assigned under FDA’s pending import regulations. They also say that low-risk importers should be subject to less scrutiny than high-risk ones.
You may also be interested in...
Program could allow for expedited entry of imports, but will be limited to 100 applicants and run for two years.
FDA has a powerful new tool to assure access to drug manufacturing plants: legislated authority to deem a product adulterated when a company tries to evade inspections: A new guidance elaborates on the situations that FDA will define as obstructionist, and cuts into new territory by defining refusal to provide records in lieu of an inspection as an actionable offence.
While COVID-19 continues to wreak havoc on FDA's ability to perform onsite preapproval inspections, new guidance offers some clarity, but the news isn't great for ANDA holders.